Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis

Daxor (Nasdaq: DXR) will exhibit its Blood Volume Analyzer (BVA™) at the MedAxiom CV Transforum Spring’26, April 30–May 2, 2026, at Sawgrass Marriott, Ponte Vedra Beach, FL.

Rhea-AI Summary

Daxor (Nasdaq: DXR) will exhibit its Blood Volume Analyzer (BVA™) at the MedAxiom CV Transforum Spring’26, April 30–May 2, 2026, at Sawgrass Marriott, Ponte Vedra Beach, FL. The company says the forum supports its commercial strategy to engage cardiovascular decision-makers and accelerate BVA adoption to inform value-based care.

According to the company, peer-reviewed studies link BVA-guided care to large outcome differences: 30‑day mortality down 82%, 1‑year mortality down 86%, 30‑day readmissions down 56%, and 55% shorter length of stay when done on admission (P<0.001).

Argus Apr 28 session

+5.39% close to close Open Argus

Details

News Market Reaction – DXR

On Apr 28, the day this news came out, DXR closed 5.39% above the previous close.

Data tracked by StockTitan Argus for the Apr 28 session.

Key Figures

30-day mortality reduction: 82% 1-year mortality reduction: 86% 30-day readmission reduction: 56% +5 more

30-day mortality reduction

82%

BVA-guided care vs standard management

1-year mortality reduction

86%

BVA-guided care vs standard management

30-day readmission reduction

56%

BVA-guided care outcomes

Length of stay reduction

55%

BVA on admission

Measurement accuracy

98%

BVA data accuracy cited in article

Revenue growth

45%

Operating division revenue growth in 2025 vs 2024

2025 operating loss

$268,598

Operating loss for 2025 (improved from 2024)

Registered direct offering

$9,000,006 gross

Offering of 765,958 shares at $11.75 per share

Historical Context

5 past events · Latest: Apr 08

5 events

1. Apr 08

   New BVA program

   24h Move

   +2.3%

   Launch of new BVA program at a high-volume Ohio cardiology center.

2. Mar 26

   Clinical data update

   24h Move

   -2.9%

   Clinical data showing BVA better detects capillary leak than common indices.

3. Mar 17

   Conference showcase

   24h Move

   +0.2%

   Showcase of next-gen portable BVA and outcome data at ACC.26.

4. Mar 10

   Product debut

   24h Move

   +1.6%

   Debut of rapid, portable blood volume analyzer at SCCM 2026.

5. Mar 09

   Investor conference

   24h Move

   -0.7%

   CEO participation and meetings at iAccess Alpha Best Ideas conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

p<0.001

1 terms

p<0.001 medical

"reduction in length of stay when done on admission (P<0.001)."

p<0.001 indicates that the chance of seeing the reported result (or something more extreme) if there were actually no real effect is less than 0.1%. For investors, that low probability means the finding is very unlikely to be a fluke—like getting nearly all heads in many coin tosses—so it raises confidence in the result, but it does not by itself prove a meaningful financial impact or establish cause-and-effect.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Oak Ridge, TN, April 28, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit its Blood Volume Analyzer (BVA^™) technology at the MedAxiom CV Transforum Spring’26 Conference. The event, being held at the Sawgrass Marriott Golf Resort & Spa, Ponte Vedra Beach, FL, from April 30 – May 2, 2026, is a premier venue for cardiovascular thought leaders and industry innovators to drive the future of cardiac care delivery.

The CV Transforum serves as a strategic touchpoint for Daxor to engage with high-level decision-makers and cardiovascular service line leaders. As hospitals increasingly shift toward value-based reimbursement models, Daxor’s BVA technology provides a clear economic and clinical value proposition.

“Our continued participation in the MedAxiom forum is a key component of our commercial strategy,” said Michael Feldschuh, CEO and President of Daxor. “By engaging directly with MedAxiom members, we are accelerating the adoption of our BVA technology. We believe this focus on high-impact clinical partnerships is essential for scaling our commercial footprint and reshaping how providers manage complex cardiovascular patients.”

BVA guided care has been shown in peer-reviewed studies to significantly improve multiple measures of patient outcomes including a reduction in 30-day mortality by 82%, 1-year mortality by 86%, 30-day readmissions by 56%, and results in a 55% reduction in length of stay when done on admission (P<0.001). BVA technology provides clinicians with 98% accurate, actionable data to optimize treatment plans and individualize care, improving outcomes while reducing duration and cost of care.

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When and where will Daxor (DXR) exhibit at MedAxiom CV Transforum Spring’26?

Daxor will exhibit April 30–May 2, 2026. According to the company, the event is at Sawgrass Marriott Golf Resort & Spa in Ponte Vedra Beach, FL, and targets cardiovascular service line leaders and decision-makers.

What outcome improvements does Daxor claim for BVA-guided care in the MedAxiom announcement?

The company cites peer-reviewed results showing large outcome declines: 30-day mortality down 82% and 1-year mortality down 86%. According to the company, studies also report 56% fewer 30-day readmissions and 55% shorter length of stay.

How does Daxor (DXR) position BVA technology for value-based reimbursement models?

Daxor says BVA offers economic and clinical value to support value-based care transitions. According to the company, BVA delivers 98% accurate, actionable data to optimize treatment and potentially reduce duration and cost of care.

Who is Daxor targeting at the MedAxiom CV Transforum for commercial adoption of BVA?

Daxor is targeting cardiovascular thought leaders and service line decision-makers. According to the company, the forum is a strategic touchpoint to engage MedAxiom members and accelerate clinical partnerships for scaling adoption.

What evidence does Daxor cite about BVA accuracy in the announcement?

The company states BVA provides 98% accurate actionable data to clinicians. According to the company, that accuracy supports individualized treatment plans and aims to improve outcomes while reducing care duration and costs.